MelanomaAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsMelanoma, ExperimentalChemotherapy, AdjuvantRadiation DosageRadiation, IonizingRadiation InjuriesSkin NeoplasmsCell Line, TumorDoxorubicinCisplatinCombined Modality TherapyNeoplasmsDose-Response Relationship, RadiationRadiation ToleranceDrug Screening Assays, AntitumorRadiationDrug Resistance, NeoplasmTreatment OutcomeRadiation ProtectionApoptosisEtoposideRadiation MonitoringCyclophosphamideBreast NeoplasmsAntineoplastic Agents, PhytogenicTumor Cells, CulturedUveal NeoplasmsPaclitaxelAntibiotics, AntineoplasticCell SurvivalLung NeoplasmsNeoplasm StagingDisease-Free SurvivalPrognosisMice, NudeSurvival AnalysisMelanoma, AmelanoticNeoplasm MetastasisRadiotherapyNeoadjuvant TherapySurvival RateXenograft Model Antitumor Assaysgp100 Melanoma AntigenVinblastineDrug Delivery SystemsRadiation OncologyCell ProliferationDrug Administration ScheduleCamptothecinTime FactorsAntineoplastic Agents, AlkylatingDose-Response Relationship, DrugAntimetabolites, AntineoplasticMethotrexateGene Expression Regulation, NeoplasticOrganoplatinum CompoundsCarboplatinNeoplasm Recurrence, LocalRadiotherapy DosageBleomycinDacarbazineNeoplasm ProteinsTaxoidsNeoplasms, Radiation-InducedGamma RaysDNA DamageDrug CarriersNeoplasm TransplantationCosmic RadiationChoroid NeoplasmsBrain NeoplasmsRadiation PneumonitisRadiation Injuries, ExperimentalRadiation-Sensitizing AgentsDeoxycytidineUltraviolet RaysP-GlycoproteinAntigens, NeoplasmDrug Resistance, MultipleNevus, PigmentedAdenocarcinomaDrug SynergismDaunorubicinRadiotherapy, AdjuvantTumor Markers, BiologicalAnthracyclinesClinical Trials as TopicOvarian NeoplasmsFollow-Up StudiesMitomycinCarcinoma, Non-Small-Cell LungCell CycleInhibitory Concentration 50MitoxantroneInduction ChemotherapyEllipticinesPlatinumAntibodies, Monoclonal